Responses
Other responses
Jump to comment:
- Published on: 21 November 2003
- Published on: 7 October 2003
- Published on: 21 November 2003Response to Marang and KievitShow More
Dear Editor
The comments of Marang and Kievit are interesting, but are they relevant?[1]
I fear not, or at best only in part. The authors have failed to answer the question, which I raised and its implication. Therefore I will try to do this myself.
1. Are medical doctors required to present medical information to a judge, if there is a likelihood that the information or evidence can be used in cour...
Conflict of Interest:
None declared. - Published on: 7 October 2003Re: Patient organisations should also establish databanks on medical complicationsShow More
Dear Editor
Gebhardt in his brief report pleads for patient organisations to establish databanks on medical complications. Given the references (e.g. to a journalist article by Paans entitled “Medical errors to be kept secret”) and the lack of argumentation, there is substantial danger of misinterpretation of the current situation, which in turn may frustrate the process of increased transparency. We would therefore li...
Conflict of Interest:
None declared.
Other content recommended for you
- Financial interests of patient organisations contributing to technology assessment at England’s National Institute for Health and Care Excellence: policy review
- Exposing drug industry funding of UK patient organisations
- Cancer patients’ organisation participation in heath policy decision-making: a snapshot/cluster analysis of the EU-28 countries
- Is the international regulation of medical complicity with torture largely window dressing? The case of Israel and the lessons of a 12-year medical ethical appeal
- Patient–physician collaboration in rheumatology: a necessity
- 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis
- Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
- Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
- Medical complications and deaths in 21 and 56 km road race runners: a 4-year prospective study in 65 865 runners—SAFER study I
- The European Statements of Hospital Pharmacy: the patient and healthcare perspective